Cancer-derived mutation in the OGA stalk domain promotes cell malignancy through dysregulating PDLIM7 and p53

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• O-GlcNAcase (OGA) is the primary enzyme removing O-GlcNAcylation, a crucial post-translational modification.
• Dysregulation of OGA is implicated in various diseases, notably cancer, but its substrate recognition and pathogenic roles are poorly understood.

Approach:

• Identified a novel cancer-derived point mutation in the non-catalytic stalk domain of OGA.
• Investigated the impact of this mutation on OGA-protein interactions and O-GlcNAc hydrolysis.
• Elucidated the mechanism by which the OGA mutant promotes cell malignancy via the p53-MDM2 pathway.

Key Points:

• A cancer-associated OGA mutation aberrantly regulates specific protein interactions and O-GlcNAc hydrolysis.
• The OGA mutant preferentially deglycosylates PDLIM7, promoting cell malignancy.
• This process involves down-regulation of the p53 tumor suppressor through transcription inhibition and MDM2-mediated ubiquitination.

Conclusions:

• Discovered a novel cancer-promoting mechanism involving OGA targeting of PDLIM7 and subsequent p53-MDM2 pathway dysregulation.
• Provided the first evidence of OGA substrate recognition occurring outside its catalytic site.
• Opened new avenues for investigating OGA's role in disease and developing targeted therapies without disrupting global O-GlcNAc levels.